Overview
Rare hereditary hemochromatosis (Orphanet code 220489) encompasses the less common genetic forms of hereditary hemochromatosis beyond the classic HFE-related (type 1) form. These rare subtypes include juvenile hemochromatosis (type 2A caused by HJV/hemojuvelin mutations and type 2B caused by HAMP/hepcidin mutations), transferrin receptor 2-related hemochromatosis (type 3, caused by TFR2 mutations), and ferroportin disease (type 4, caused by SLC40A1 mutations). All forms are characterized by excessive iron absorption from the diet, leading to progressive iron overload in multiple organ systems. The liver, heart, pancreas, endocrine glands, joints, and skin are primarily affected. Clinical features vary by subtype but commonly include liver disease (hepatomegaly, fibrosis, cirrhosis, and increased risk of hepatocellular carcinoma), cardiomyopathy, diabetes mellitus, hypogonadotropic hypogonadism, arthropathy, skin hyperpigmentation (bronze discoloration), and fatigue. Juvenile forms (type 2) tend to present earlier in life, often before age 30, with more severe cardiac and endocrine involvement, whereas type 3 resembles classic hemochromatosis in its clinical course. Ferroportin disease (type 4) has a distinct pathophysiology and may present with predominant macrophage iron loading and variable tolerance to phlebotomy. Diagnosis involves elevated serum ferritin and transferrin saturation, confirmed by genetic testing. Treatment primarily consists of therapeutic phlebotomy (regular blood removal) to reduce iron stores and prevent organ damage. In patients who cannot tolerate phlebotomy, iron chelation therapy may be used. Early diagnosis and treatment can prevent irreversible organ damage and significantly improve prognosis. Dietary modifications, including avoidance of iron supplements and limiting alcohol consumption, are also recommended as supportive measures.
Also known as:
Variable
Can be inherited in different ways depending on the underlying gene
Variable
Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
1 eventUniversity of Wisconsin, Madison
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Rare hereditary hemochromatosis.
1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Rare hereditary hemochromatosis.
Community
No community posts yet. Be the first to share your experience with Rare hereditary hemochromatosis.
Start the conversation →Latest news about Rare hereditary hemochromatosis
Disease timeline:
New recruiting trial: Fully Automated High-Throughput Quantitative MRI of the Liver
A new clinical trial is recruiting patients for Rare hereditary hemochromatosis
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Rare hereditary hemochromatosis
What is Rare hereditary hemochromatosis?
Rare hereditary hemochromatosis (Orphanet code 220489) encompasses the less common genetic forms of hereditary hemochromatosis beyond the classic HFE-related (type 1) form. These rare subtypes include juvenile hemochromatosis (type 2A caused by HJV/hemojuvelin mutations and type 2B caused by HAMP/hepcidin mutations), transferrin receptor 2-related hemochromatosis (type 3, caused by TFR2 mutations), and ferroportin disease (type 4, caused by SLC40A1 mutations). All forms are characterized by excessive iron absorption from the diet, leading to progressive iron overload in multiple organ systems.
Are there clinical trials for Rare hereditary hemochromatosis?
Yes — 1 recruiting clinical trial is currently listed for Rare hereditary hemochromatosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Rare hereditary hemochromatosis?
24 specialists and care centers treating Rare hereditary hemochromatosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.